Evidence map›Paper›PMID 30010650›Full record

ArticleJournal of visualized experiments : JoVE2018

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia.

Travis B Nielsen, Jun Yan, Brian Luna, Brad Spellberg

Open access · bronzeAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Defining the role ofJournal of bacteriology · 2026
    Article
  5. Specialized Pro-Resolving Mediators MaR1 and LXAThe American journal of pathology · 2026
    Article
  6. Resistance, heteroresistance, and fitness costs drive colistin treatment failure duringProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Ceftazidime retainsmSphere · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Travis B NielsenDepartment of Molecular Microbiology and Immunology, University of Southern California; travis.nielsen@gmail.com.
Jun YanDepartment of Molecular Microbiology and Immunology, University of Southern California.
Brian LunaDepartment of Molecular Microbiology and Immunology, University of Southern California.
Brad SpellbergDepartment of Molecular Microbiology and Immunology, University of Southern California; Division of Infectious Diseases, Department of Medicine, LAC+USC Medical Center.
University of Southern California · US

Funding

MAb Passive Vaccination against Acinetobacter baumanniiR01AI130060 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRAD J SPELLBERG · 2017 to 2026
$6.7M
Humanized Monoclonal Antibody to Treat Acinetobacter InfectionsR42AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI ISLAM, KHALID · 2016 to 2018
$3.1M
Transferrin Combination Therapy to Address Antimicrobial ResistanceR01AI117211 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2016 to 2019
$2.7M
Humanized Monoclonal Antibodies to Treat Acinetobacter InfectionsR41AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI SPELLBERG, BRAD J · 2013 to 2014
$574k
Diabetes and Inflammation During InfectionR21AI127954 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2017 to 2018
$454k
NIAID NIH HHS R01 AI117211NIAID NIH HHS R01 AI130060NIAID NIH HHS R21 AI127954NIAID NIH HHS R41 AI106375NIAID NIH HHS R42 AI106375
6 · The paper itself

Abstract

Murine infection models are critical for understanding disease pathogenesis and testing the efficacy of novel therapeutics designed to combat causative pathogens. Infectious pneumonia is among the most common infections presented by patients in the clinic and thus warrants an appropriate in vivo model. Typical pneumonia models use intranasal inoculation, which deposits excessive organisms outside the lung, causing off-target complications and symptoms, such as sinusitis, gastritis, enteritis, physical trauma, or microparticle misting to mimic aerosol spread more typical of viral, tuberculous, or fungal pneumonia. These models do not accurately reflect the pathogenesis of typical community- or healthcare-acquired bacterial pneumonia. In contrast, this murine model of oropharyngeal aspiration pneumonia mimics the droplet route in healthcare-acquired pneumonia. Inoculating 50 µL of the bacteria suspension into the oropharynx of anesthetized mice causes reflexive aspiration, which results in pneumonia. With this model, one can examine the pathogenesis of pneumonia-causing pathogens and new treatments to combat these diseases.

Indexed as

AnimalsDisease Models, AnimalHumansLungMiceOropharynxPneumonia, AspirationPneumonia, BacterialPneumonia, Ventilator-Associated

Identifiers

PMID30010650
PMCPMC6102004
OpenAlexW2811265246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.